Elizabeth Schneider: Revolutionary Drug Shows Promise for Primary Ovarian Insufficiency
Elizabeth Schneider, Staff Product Marketing Manager at Illumina, shared a post on LinkedIn:
“Primary ovarian insufficiency (POI), in which the ovaries don’t mature and release eggs properly, affects about 3% of women under age 40 and typically causes infertility. But a drug already approved to treat kidney disease may one day help some of these people get pregnant, a research team reports today in Science.
In studies of mouse ovarian tissue and live mice, the drug, called finerenone, kick-started the growth of tiny egg-containing sacs, or follicles—a process that’s often defunct in people with POI. In a small clinical trial, people with POI who were given the drug went on to produce mature eggs that could be harvested, and some of the eggs were then successfully fertilized in the lab.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Apr 19, 2026, 10:54Vipin Chandra: Impact of Environmental Pollution on Sperm DNA Fragmentation
-
Apr 19, 2026, 10:45Ting Yuan: Why PGT-A Normal Embryos Can Have Different Outcomes
-
Apr 19, 2026, 10:41Exploring Public Perspectives on Mitochondrial Disease and Donation – RBMO
-
Apr 19, 2026, 10:14Triggering IVF Too Early May Reduce Egg and Embryo Potential – Fertility Plus
-
Apr 19, 2026, 09:51ACOG Publishes Updated Guidance on Evaluation of Postmenopausal Bleeding – ACOG
-
Apr 19, 2026, 09:19First Birth Rates After Surgically Verified Endometriosis Subtypes – Fertility and Sterility
-
Apr 19, 2026, 09:14Emma Nash et al. Examine Psychosocial Challenges in Donor Sperm Care – RBMO
-
Apr 19, 2026, 08:59The Impact of Endometrial Fluid on Single Euploid Frozen Embryo Transfers – ReproScientifics – SpermTracer
-
Apr 19, 2026, 08:02From Clinical Guidelines to Molecular Insights of PCOS – Cooperation IVF